Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Why Is Abbott (ABT) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.
by Zacks Equity Research
Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Abbott Laboratories, Baxter International, ResMed and Intuitive Surgical
3 Stocks to Capitalize on Promising Medical Products Industry
by Trina Mukherjee
Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.
Top Stock Reports for Microsoft, Tesla & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Tesla (TSLA) and AT&T (T).
Surging Earnings Estimates Signal Upside for Abbott (ABT) Stock
by Zacks Equity Research
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark
by Zacks Equity Research
BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.
OPKO Health's (OPK) BioReference Laboratories Unveils New Test
by Zacks Equity Research
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid
by Zacks Equity Research
In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.
Verizon (VZ), Abbott (ABT), Thermo Fisher (TMO) Report Q3; Tesla (TSLA) After the Bell
by Mark Vickery
Thermo Fisher (TMO) posted a big beat this morning, while Verizon (VZ) and Abbott (ABT) topped expectations more mildly.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q3.
Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 8.89% and 4.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Abbott (ABT) Might Surprise This Earnings Season
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from gradual recovery in Clear Aligner shipment volumes in Q3.
Calix (CALX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Backed by a robust balance sheet, Calix's (CALX) third-quarter earnings are likely to have been driven by technological innovations for upgraded products.
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, NextEra Energy, Silgan Holdings, UniFirst Corp and Landstar System
Intuitive Surgical (ISRG) Q3 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect improvement in procedure volume.
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal fourth-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
COVID-19 Antigen Test Launch to Drive Abbott (ABT) Q3 Earnings
by Zacks Equity Research
Abbott (ABT) is expected to register strong sales in the Adult Nutrition category, banking on growing global demand for its nutrition brand Ensure.
An Investment Strategy for Q3 Earnings in a Volatile Market
by Nalak Das
Investment in low-beats stocks with a favorable Zacks Rank and positive Earnings ESP will be a sound strategy to enhance one's portfolio.
Abbott (ABT) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $107.75, marking a -0.57% move from the previous day.
Boston Scientific Gets a Boost From MedSurg Arm Amid Coronavirus
by Zacks Equity Research
Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.